摘要
目的研究应用阿托伐他汀对急性冠脉综合征患者血清MMP-9、MMP-2及hs-CRP的影响。方法选择ACS患者61例,稳定型心绞痛患者19例及正常对照组30例。随机将ACS患者分为阿托伐他汀组(33例)和常规组(28例),比较各组间血清MMP-9、MMP-2及hs-CRP的水平变化。结果 ACS组与SA组及正常对照组之间血清MMP-9、MMP-2及hs-CRP水平相比差异有统计学意义,两组干预后血清MMP-9、MMP-2及hs-CRP水平相比差异有统计学意义(P<0.05)。结论阿托伐他汀可降低ACS患者血清MMP-9、MMP-2及hs-CRP水平,减少冠状动脉粥样斑块基质成分的降解和炎症反应,从而起到稳定动脉粥样硬化斑块的作用。
Objective To investigate the influences of atuovastatin on serumMMP-9,MMP-2,and hs-CRP levels of patients with acute coronary syndrome.Methods There were 61 patients with ACS and 19 patients with SA.Meanwhile,30 cases of age matched control individuals were selected.Then 61 patients with ACS were randomly divided into two groups：atuovastatin treatment group and regular treatment group.The serum level of MMP-9,MMP-2 and hs-CRP were compared among all groups.Results There was significant difference in serum level of MMP-9,MMP-2 and hs-CRP between ACS group and SA group and control group.There was significant difference in serum level of MMP-9,MMP-2 and hs-CRP between atuovastatin treatment group and regular treatment group after treatment.Conclusion Atuovastatin could decrease the breakdown of matrix collagen and reduce inflammatory reaction,and it might have a beneficial effect on steadying the plaque.
出处
《中国医药科学》
2011年第10期15-16,25,共3页
China Medicine And Pharmacy
基金
吉林省长春市社会发展计划项目(编号:08SF23)
